Cefazolin Prophylaxis for Total Joint Arthroplasty: Obese Patients Are Frequently Underdosed and at Increased Risk of Periprosthetic Joint Infection by Rondon, Alexander J. et al.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Cefazolin Prophylaxis for Total Joint Arthroplasty: Obese Patients are Frequently 
Underdosed and at Increased Risk for Periprosthetic Joint Infection 
Running Title: Cefazolin Dosing in TJA 
Alexander J. Rondon, MD, MBA1
Michael M. Kheir, MD2
Timothy L. Tan, MD1
Noam Shohat, MD1,3  
Max R. Greenky, MD1
Javad Parvizi, MD, FRCS1
1The Rothman Institute at Thomas Jefferson University, Philadelphia, PA 19107 
2 Department of Orthopaedics at Indiana University, Indianapolis, IN 46202 
3
 Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel  
Corresponding Author: 
Javad Parvizi, MD, FRCS 
The Rothman Institute 
125 S 9th St. Ste 1000 
Philadelphia, PA 19107 
P: 267-339-7813 
F: 215-503-5651 
parvj@aol.com 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Rondon, A. J., Kheir, M. M., Tan, T. L., Shohat, N., Greenky, M. R., & Parvizi, J. (2018). Cefazolin Prophylaxis for 
Total Joint Arthroplasty: Obese Patients are Frequently Underdosed and at Increased Risk for Periprosthetic Joint 
Infection. The Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2018.06.037
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
Cefazolin Prophylaxis for Total Joint Arthroplasty: Obese Patients are Frequently 1 
Underdosed and at Increased Risk for Periprosthetic Joint Infection 2 
Running Title: Cefazolin Dosing in TJA 3 
4 
5 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
ABSTRACT 6 
Background: One of the most effective prophylactic strategies against periprosthetic joint 7 
infection (PJI) is administration of perioperative antibiotics. Many orthopaedic surgeons 8 
are unaware of the weight-based dosing protocol for cefazolin. This study aimed to 9 
elucidate what proportion of patients receiving cefazolin prophylaxis are underdosed and 10 
whether this increases the risk for PJI.  11 
 12 
Methods: A retrospective study of 17,393 primary total joint arthroplasties (TJA) 13 
receiving cefazolin as perioperative prophylaxis from 2005-2017 was performed. Patients 14 
were stratified into two groups (underdosed and adequately dosed) based on patient 15 
weight and antibiotic dosage. Patients that developed PJI within 1-year following index 16 
procedure were identified. A bivariate and multiple logistic regression analysis were 17 
performed to control for potential confounders and identify risk factors for PJI.  18 
 19 
Results: The majority of patients weighing greater than 120 kg (95.9%, 944/984) were 20 
underdosed. Underdosed patients had a higher rate of PJI at 1-year compared with 21 
adequately dosed patients (1.51% vs. 0.86%, p=0.002). Patients weighing greater than 22 
120 kg had higher 1-year PJI rate than patients weighing less than 120 kg (3.25% vs. 23 
0.83%, p<0.001).  Patients who were underdosed (odds ratio (OR) 1.665, p=0.006) with 24 
greater comorbidities (OR 1.259, p<0.001) were more likely to develop PJI at 1-year. 25 
 26 
Conclusion: Cefazolin underdosing is common, especially for patients weighing more 27 
than 120 kg. Our study reports that underdosed patients were more likely to develop PJI. 28 
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Orthopaedic surgeons should pay attention to the weight-based dosing of antibiotics in 29 
the perioperative period to avoid increasing risk for PJI.  30 
 31 
Keywords: Total Joint Arthroplasty; Periprosthetic Joint Infection; Perioperative 32 
Antibiotics; Obesity; Dosing; Risk 33 
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INTRODUCTION   35 
One of the most effective strategies for prevention of periprosthetic joint infection 36 
(PJI) has been the administration of perioperative antibiotics.  The presence of antibiotics 37 
in the serum can eliminate the bacteria that gain access to the surgical site during total 38 
joint arthroplasty (TJA) and in turn reduce the incidence of surgical site infection [1]. 39 
Current practice is to administer first or second generation cephalosporin to all patients 40 
undergoing TJA, unless contraindicated [2]. Despite the widespread use of cefazolin as a 41 
perioperative antibiotic for TJA patients, many surgeons are unaware of cefazolin’s 42 
weight-based dosing. Thus, the goals of the present study are (1) to ascertain what 43 
proportion of TJA patients receiving cefazolin are adequately dosed and (2) if under-44 
dosing was associated with increased risk of subsequent PJI.  45 
At our institution, the recommended dose of cefazolin has traditionally been 2 46 
grams intravenously. Current guidelines for antimicrobial prophylaxis recommend 47 
weight-based dosing protocols starting the cefazolin dose at 1 gram (g) if a patient weighs 48 
less than 60 kilograms (kg), 2 grams if patient weights between 60 kg and 120 kg, and 3 49 
grams if patient weight over 120 kg [2,3]. A previous study at our institution found the 50 
majority of patients receiving vancomycin as perioperative prophylaxis were underdosed 51 
according to weight-based dosage recommendations (15 milligrams/kg) [4].  52 
Given the increasing prevalence of obesity [5,6] in the TJA population, many 53 
patients may be inadequately dosed for antibiotics. Thus, the effective drug concentration 54 
may not be met to provide bactericidal effects and subsequently may predispose patients 55 
to an increased risk for PJI. We hypothesis patients who are underdosed are at increased 56 
risk of adverse events and infection.   57 
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 58 
MATERIALS AND METHODS 59 
After Institutional Review Board approval, a retrospective review of 24,439 60 
patients undergoing primary TJA at a single institution was performed from 2005-2017. 61 
All patients with primary TJA, with record of the perioperative antibiotic and dosage 62 
administrated were included in this study. Patients with aseptic revision TJA were 63 
excluded. The perioperative antibiotic and dosage were then obtained for the patient 64 
population, resulting in a cohort of 17,393 of patients receiving cefazolin as perioperative 65 
prophylactic antibiotic.  Patients who received other types of perioperative prophylactic 66 
antibiotics (i.e. Vancomycin) other than Cefazolin were excluded from the study. Patients 67 
with a history of prior infection in the same joint or unavailable antibiotic information 68 
were excluded from the study. An electronic query and chart review was then performed 69 
to identify demographic information, height, weight, body mass index (BMI), joint, 70 
laterality, length of stay, operative time, time to incision from administration of cefazolin, 71 
and Charlson comorbidities. Demographic information of the cohort is presented in Table 72 
1.  73 
Using the generalized dosing protocol of 1 g for patients weighing below 60 kg, 2 74 
g for patients weighing between 60 kg and 120 kg, and 3 g for patients weighing 120 kg 75 
or greater for cefazolin, proper dosage was calculated for each patient. These values were 76 
then compared to the actual dose given to the patients at time of surgery. Patients were 77 
assessed as either underdosed (< 1 g, if patient weighed between 60 kg-120 kg and was 78 
given <2g, or if patient weighed 120 kg or more and was given < 3 g) or adequately 79 
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dosed (if appropriately dosed based on weight). Cefazolin was administered within 60 80 
minutes of incision in all cases. 81 
The cohort was then cross-referenced with an institutional PJI database to identify 82 
patients with PJI. We defined PJI in patients based on the International Consensus 83 
Meeting criteria[7]. A subsequent manual chart review was undertaken to verify PJI 84 
outcomes and ensure the correct joint and laterality.  85 
 The primary endpoint was to assess the incidence of 1-year PJI following TJA in 86 
patients who were underdosed versus adequately dosed.   87 
Statistical Analysis 88 
All statistical analyses were performed with PJI rate analyzed among the two 89 
dosing groups and by weight class. Bivariate analyses were performed to compare 90 
demographics, perioperative variables between the two dosing groups and weight class. 91 
A multivariate logistic regression model was utilized to determine risk factors for PJI 92 
based on the following: antibiotic dosing, dosing status, age, patient weight, BMI, gender, 93 
joint, length of stay, and Charlson Comorbidity index. All statistical analyses were 94 
performed using R 2.15.1 (R Foundation for Statistical Computing, Vienna, Austria) and 95 
an alpha level of 0.05 was used to evaluate significance. All analyses were conducted 96 
with Generalized estimating equations (GEE) to account for the clustering within patients 97 
who had multiple admissions. The GEE specified a binary distribution with a logit link 98 
for analyzing the dichotomous outcomes.   99 
 100 
RESULTS 101 
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All patients included in the study received cefazolin preoperatively within 60 102 
minutes as the main antibiotic prophylaxis. Of the 984 patients weighing 120 kg or 103 
greater, the majority were underdosed (95.9%, 944/984). For patients weighing less than 104 
120 kg, most were adequately dosed (88.3%, 14,497/16,409). Overall, 83.6% 105 
(14,537/17,393) of patients were adequately dosed for cefazolin prophylaxis. Of note, 106 
0.10% (18/17,393) patients were overdosed, however, none developed PJI at 1-year and 107 
all weighed between 60 and 120 kg.  108 
Among primary TJAs, underdosed patients had a higher rate of 1-year PJI 109 
compared with adequately dosed patients (1.51% vs. 0.86%, p=0.002). When stratified by 110 
weight, patients weighing greater than or equal to 120 kg had higher 1-year PJI rate than 111 
patients weighing less than 120 kg (3.25% vs. 0.83%, p<0.001)  (Table 1).  112 
Bivariate analysis demonstrated that patients who were underdosed (adjusted odds 113 
ratio (OR) 1.762, p=0.002), male (OR 1.517, p=0.014), those with greater comorbidities 114 
(OR 1.251, p<0.001), and higher weight (OR 1.025, p<0.001) were more likely to 115 
develop PJI within 1-year (Table 2). Following multivariate regression analyses, these 116 
trends remained significant with underdosed (OR 1.665, p=0.006) and patients with 117 
greater comorbidities (OR 1.259, p<0.001) having a higher rate of PJI at 1-year (Table 3). 118 
 119 
DISCUSSION 120 
The efficacy and value of perioperative antibiotics for surgical prophylaxis has 121 
been proven in the literature [8]. Recent studies have supported current universal 122 
antibiotic prophylaxis versus providing treatment based on individual comorbidities[9]. 123 
The most appropriate antibiotic therapy recommended for patients undergoing TJA is a 124 
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first or second generation cephalosporin due to its broad spectrum of action, cost 125 
effectiveness, and ability to cover both gram positive and gram negative organisms 126 
[3,10,11]. Furthermore, cephalosporins are bactericidal and have excellent distribution 127 
profiles in synovium, muscle, hematomas, and bone [12]. The current American 128 
Academy of Orthopaedic Surgeons (AAOS) guidelines recommend patients receive 129 
prophylactic antibiotics within one hour prior to surgical incisions and be discontinued 130 
within 24 hours following the end of surgery [13].   131 
The literature has previously reported on the necessity for weight-based dosing of 132 
perioperative antibiotics. While the current guidelines from the Center for Disease 133 
Control and Prevention, World Health Organization, and National Institute for Healthcare 134 
and Excellence do not provide dosing recommendation, the Society for Healthcare 135 
Epidemiology of America and the International Consensus Meeting (ICM) on PJI 136 
strongly agreed that preoperative antibiotics weight-based dosing is valid and warranted 137 
[2,14,15,3,16]. However, for adult patients, standard antibiotic dosing remains a common 138 
practice as it is safe, effective, and conveniently avoids the need for calculations, thus 139 
reducing the potential for medication errors[17]. Different ranges for perioperative 140 
cefazolin dosing protocols has been reported from standard adult dose of 2 g [18] to 141 
weight-based dosing of 1 g for patients weighing less than 80 kg or 2 g for patients 142 
weighing greater than 80 kg [19]. The American Society of Health-System Pharmacists 143 
(ASHP) recommends a weight-based protocol of 1 g from patients weighing less than 60 144 
kg, 2 g for patients weighing 60-120 kg, and 3 g for patients weighing 120 kg or more 145 
[3]. Our institution follows these weight-based guidelines utilizing both 60 kg and 120 kg 146 
cutoffs, however, as illustrated by the results of the present study, the majority of patient 147 
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weighing above 120 kg were underdosed by recieving 2 g of antibiotics. Similar to our 148 
5.7% rate of patients weighing greater than 120 kg, the prevalence of extreme obesity 149 
(BMI > 40) in the United States has been reported at 7.7% [5,20]. When assuming 150 
estimates of 1,000,000 TJA performed annually and an underdosing rate of greater than 151 
90% for the extreme obese population, fifty thousand TJA patients are likely underdosed 152 
each year [21].  Given the significant rise in obesity and morbid obesity, increased 153 
scrutiny with respect to perioperative antibiotic prophylaxis is warranted to ensure that 154 
this population is not underdosed [5,6].  155 
The literature has previously reported on factors affecting the dosing of 156 
perioperative antibiotics, specifically patient weight. One study demonstrated that 2 g of 157 
cefazolin provided 5 hours of adequate levels of prophylactic protection for patients 158 
regardless of their BMI [18]. Edminston et al. reported on cefazolin serum concentrations 159 
in morbidly obese undergoing gastric bypass, concluding that 2 g of cefazolin may not be 160 
sufficient for patients with a BMI of 50 Kg/m2 or greater [22]. A prospective randomized 161 
controlled trial (RCT) of morbidly obese patients undergoing gastroplasty reported 162 
decreased wound infection rate from 16.5% to 5.6% when cefazolin dosed was increased 163 
from 1 g to 2 g [23]. In contrast to our study, Kheir et al. found a comparable PJI rate 164 
among stratified vancomycin dosage groups (underdosed 2%, adequately dosed 2%, 165 
overdosed 2%, p=0.995), however reported that 64% of patients receiving vancomycin as 166 
prophylaxis were underdosed and overall patients receiving vancomycin prophylaxis 167 
were at an increased risk of PJI (OR 1.587, p=0.048) compared to patients receiving 168 
cefazolin prophylaxis [4]. Sharareh et al. found no difference in cefazolin concentration 169 
in trabecular bone with respect to patient weight [24]. Additionally, Manrique et al. 170 
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reported that patients undergoing total knee arthroplasty (TKA) who were underweight 171 
had a higher likelihood of surgical site infection compared to other weight groups [25]. 172 
However, we do recognize that the majority of these studies report results by BMI as 173 
opposed to weight, which may create confusion as dosing is based on weight not BMI. 174 
The present study reports data by weight category as opposed to BMI. 175 
The present study has several limitations. First, the retrospective nature of the 176 
study is subject to the inherent bias of retrospective work. Second, underdosed patients 177 
weighing greater than 120 kg may have been predisposed to adverse conditions due to 178 
morbidity associated with obesity rather than inadequate dosing of cefazolin. Third, 179 
despite having more than 17,000 patients, we may still be underpowered given the low 180 
rate of PJI. Fourth, the present study encompasses a large time-period and there may be 181 
protocol changes over this time-period that may not be accounted for. Fifth, while our 182 
study primarily focuses on weight, other factors that influence antibiotic dosing such as 183 
liver and kidney function, gender, and fat distribution were not considered. However, 184 
despite the aforementioned limitations, the present study does bring to light important 185 
dosing considerations when treating patients weighing 120 kg or more.  186 
 Perioperative antibiotics remain an important strategy in protection against PJI, 187 
one of the most devastating complications following TJA. While the majority of patients 188 
remain adequately dosed, underdosing of cefazolin in the obese patient is common. We 189 
suggest orthopaedic surgeons incorporate proper weight based antibiotic dosing in their 190 
preoperative planning. Orthopaedic surgeons must be vigilant when treating patients 191 
weighing 120 kg or greater as failure to adequately dose their perioperative antibiotics 192 
can unnecessarily predispose this population to PJI.  193 
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Table 1: Demographic information and dosing information  
 
Cohort (n= 17,393) 
  
Adequately 
Dosed 
(n=14,537) 
Underdosed 
(n=2,856) P value 
Age (year) 63.5 (0.09) 63.5 (0.22) 0.849 
Gender (male) 6417 (44.1%) 1736 (60.8%) <0.001 
BMI  29.55 (0.04) 32.11 (0.13) <0.001 
Weight (kg) 84.41 (0.14) 97.17 (0.49) <0.001 
CCI 0.391 (0.01) 0.386 (0.02) <0.001 
Joint (knee) 6895 (47.4%) 1320 (46.2%) 0.235 
LOS 2.67 (0.02) 3.05 (0.05) <0.001 
90 day Readmission 555 (3.8%) 128 (4.5%) 0.113 
1-year PJI  125 (0.86%) 43 (1.51%) 0.002 
Stratified by Weight  
  
 < 120 kg 
(n=16,409) 
≥ 120 kg 
(n=984) P value 
Age (year) 63.9 (0.09) 57.8 (0.29) 0.039 
CCI 0.387 (0.01) 0.441 (0.03) 0.100 
Joint (knee) 8047 (46.6%) 567 (57.8%) <0.001 
LOS 2.71 (0.02) 3.11 (0.08) 0.618 
90 day Readmission 614 (3.7%) 69 (7.0%) <0.001 
Underdosed 1912 (11.7%) 944 (95.9%) <0.001 
1-year PJI  136 (0.83%) 32 (3.25%) <0.001 
 
Data presented in table as mean (standard error) or number (percentage) 
Abbreviations: BMI, Body Mass Index; kg, kilogram; CCI, Charlson Comorbidity index; LOS, 
Length of Stay; PJI, Periprosthetic Joint Infection 
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Table 2: Bivariate analysis of Cefazolin and 1-year PJI  
  
Adjusted 
Odds 
Ratio P Value 
Underdosed 1.762 0.002 
Gender (male) 1.517 0.014 
Joint (knee) 0.900 0.512 
Younger Age (year) 1.010 0.174 
Weight (kg) 1.025 <0.001 
BMI 1.080 <0.001 
CCI 1.251 <0.001 
Abbreviations: PJI, Periprosthetic Joint Infection; kg, kilogram; BMI, Body Mass Index; CCI, 
Charlson Comorbidity index 
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Table 3: Multivariate analysis for weight-based dosing of Cefazolin and likelihood of PJI  
Regression 
 
Adjusted 
Odds Ratio P Value 
Underdosed 1.665 0.006 
Gender (male) 1.372 0.067 
Younger Age (year) 1.011 0.130 
CCI 1.259 <0.001 
Abbreviations: PJI, Periprosthetic Joint Infection; kg, kilogram; CCI, Charlson Comorbidity 
index 
 
